LCGLA
ADCT icon

LYNX CAPITAL GROUP LTD /ADV’s ADC Therapeutics ADCT Stock Holding History

LYNX CAPITAL GROUP LTD /ADV’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		$24.9K Buy
+15,000
New +$13.8K 0.02% 81

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
VCG
Vantage Consulting Group Virginia Beach, Virginia $19.7M AUM 280.87% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

LYNX CAPITAL GROUP LTD /ADV's ADCT Position: Q4 2023 in Review

LYNX CAPITAL GROUP LTD /ADV opened a new position in ADC Therapeutics (ADCT) in Q4 2023: 15,000 shares worth $24.9K. The stake represents 0.02% of the portfolio and ranks #81 among its holdings.

38 funds tracked by Wall St. Rank hold ADCT as of Q4 2023.

  • LYNX CAPITAL GROUP LTD /ADV held 15,000 shares of ADC Therapeutics worth $24.9K as of Q4 2023.
  • ADC Therapeutics was a new LYNX CAPITAL GROUP LTD /ADV position in Q4 2023.
  • ADC Therapeutics made up 0.02% of LYNX CAPITAL GROUP LTD /ADV's portfolio in Q4 2023, its #81 holding.
  • 38 funds tracked by Wall St. Rank held ADC Therapeutics as of Q4 2023.

Based on LYNX CAPITAL GROUP LTD /ADV's 13F filing for Q4 2023, filed 7 Aug 2026.